[{"id":"7a52caf1-0dfe-4289-a790-01f8d7b2993f","acronym":"DUAL-CAR-NK-GB","url":"https://clinicaltrials.gov/study/NCT07480941","created_at":"2026-03-28T01:39:30.783Z","updated_at":"2026-03-28T01:39:30.783Z","phase":"Phase 1","brief_title":"Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma","source_id_and_acronym":"NCT07480941 - DUAL-CAR-NK-GB","lead_sponsor":"Beijing Biotech","biomarkers":" EGFR • CD276 • IL13RA2","pipe":" | ","alterations":" EGFR wild-type","tags":["EGFR • CD276 • IL13RA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/02/2026","start_date":" 02/02/2026","primary_txt":" Primary completion: 02/18/2027","primary_completion_date":" 02/18/2027","study_txt":" Completion: 03/17/2028","study_completion_date":" 03/17/2028","last_update_posted":"2026-03-18"},{"id":"c31fe31a-3823-4e8c-81cc-892c70bccfed","acronym":"","url":"https://clinicaltrials.gov/study/NCT07206849","created_at":"2025-10-11T01:31:02.610Z","updated_at":"2025-10-11T01:31:02.610Z","phase":"Phase 2","brief_title":"Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)","source_id_and_acronym":"NCT07206849","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ojemda (tovorafenib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 03/01/2026","start_date":" 03/01/2026","primary_txt":" Primary completion: 03/01/2030","primary_completion_date":" 03/01/2030","study_txt":" Completion: 03/01/2037","study_completion_date":" 03/01/2037","last_update_posted":"2025-10-03"},{"id":"4ea3c927-ac32-4c7f-8a28-7189b90c8ff5","acronym":"","url":"https://clinicaltrials.gov/study/NCT07180927","created_at":"2025-09-20T07:04:28.868Z","updated_at":"2025-09-20T07:04:28.868Z","phase":"Phase 1/2","brief_title":"DLL3 CAR-T Therapy Targeting Brain Tumors","source_id_and_acronym":"NCT07180927","lead_sponsor":"Shenzhen Geno-Immune Medical Institute","biomarkers":" DLL3","pipe":"","alterations":" ","tags":["DLL3"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/10/2025","start_date":" 09/10/2025","primary_txt":" Primary completion: 12/31/2028","primary_completion_date":" 12/31/2028","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2025-09-18"},{"id":"fd69b3ec-1305-4dd1-87d3-4b0c8f4a1b9a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04661384","created_at":"2025-06-07T14:44:26.057Z","updated_at":"2025-06-07T14:44:26.057Z","phase":"Phase 1","brief_title":"Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma","source_id_and_acronym":"NCT04661384","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD123","pipe":"","alterations":" ","tags":["CD123"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MB-101"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/05/2021","start_date":" 03/05/2021","primary_txt":" Primary completion: 11/17/2025","primary_completion_date":" 11/17/2025","study_txt":" Completion: 11/17/2025","study_completion_date":" 11/17/2025","last_update_posted":"2025-06-03"},{"id":"a9f39237-1737-4421-910a-0e37d38262b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05083754","created_at":"2023-11-27T22:14:37.322Z","updated_at":"2025-02-25T12:28:25.580Z","phase":"Phase 1","brief_title":"Carmustine Wafer in Combination With Retifanlimab and Radiation With/Without Temozolomide in Subjects With Glioblastoma","source_id_and_acronym":"NCT05083754","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" PD-L1 • MSI • CD8 • PD-1 • CD4 • ICOS","pipe":"","alterations":" ","tags":["PD-L1 • MSI • CD8 • PD-1 • CD4 • ICOS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • carmustine • Zynyz (retifanlimab-dlwr)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 08/31/2022","start_date":" 08/31/2022","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2027","study_completion_date":" 01/01/2027","last_update_posted":"2025-02-24"},{"id":"42d928bf-01a8-4f38-bc3e-dbcbf7fa205e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06161974","created_at":"2023-12-08T22:16:35.701Z","updated_at":"2025-02-25T13:41:56.353Z","phase":"Phase 2","brief_title":"Study of Olutasidenib and Temozolomide in HGG","source_id_and_acronym":"NCT06161974","lead_sponsor":"Rigel Pharmaceuticals","biomarkers":" IDH1","pipe":" | ","alterations":" IDH1 mutation","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Rezlidhia (olutasidenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/01/2025","start_date":" 03/01/2025","primary_txt":" Primary completion: 06/01/2029","primary_completion_date":" 06/01/2029","study_txt":" Completion: 06/01/2035","study_completion_date":" 06/01/2035","last_update_posted":"2025-02-21"},{"id":"593b542b-470d-465e-ae6a-8f9b079a6849","acronym":"ALLIANCE-ABTC-1604","url":"https://clinicaltrials.gov/study/NCT03107780","created_at":"2021-01-18T15:18:36.892Z","updated_at":"2025-02-25T13:48:22.462Z","phase":"Phase 1","brief_title":"Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer","source_id_and_acronym":"NCT03107780 - ALLIANCE-ABTC-1604","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • MGMT","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53 • MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navtemadlin (KRT-232)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/09/2018","start_date":" 07/09/2018","primary_txt":" Primary completion: 03/21/2019","primary_completion_date":" 03/21/2019","study_txt":" Completion: 02/07/2026","study_completion_date":" 02/07/2026","last_update_posted":"2025-02-21"},{"id":"ae6dde76-a9e2-4ffe-85b4-d60ff795f82d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03919292","created_at":"2021-01-18T19:17:11.532Z","updated_at":"2025-02-25T13:48:40.499Z","phase":"Phase 1/2","brief_title":"Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca","source_id_and_acronym":"NCT03919292","lead_sponsor":"Virginia Commonwealth University","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • RAS mutation","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 83","initiation":"Initiation: 05/01/2019","start_date":" 05/01/2019","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2026","study_completion_date":" 05/31/2026","last_update_posted":"2025-02-21"},{"id":"2d273f1a-d076-4196-b160-67a7c935aa6c","acronym":"NCI-2014-01488","url":"https://clinicaltrials.gov/study/NCT02208362","created_at":"2021-03-16T19:52:14.281Z","updated_at":"2025-02-25T14:06:49.902Z","phase":"Phase 1","brief_title":"Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma","source_id_and_acronym":"NCT02208362 - NCI-2014-01488","lead_sponsor":"City of Hope Medical Center","biomarkers":" IL13RA2","pipe":" | ","alterations":" CD123 expression","tags":["IL13RA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD123 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MB-101"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 05/18/2015","start_date":" 05/18/2015","primary_txt":" Primary completion: 02/08/2021","primary_completion_date":" 02/08/2021","study_txt":" Completion: 07/08/2025","study_completion_date":" 07/08/2025","last_update_posted":"2025-02-19"},{"id":"3c5d0961-29c6-44c5-9f18-012dc3b4ae3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT06504381","created_at":"2025-02-25T14:04:35.935Z","updated_at":"2025-02-25T14:04:35.935Z","phase":"Phase 1/2","brief_title":"DB107-RRV, DB107-FC, and Radiation Therapy with or Without Temozolomide (TMZ) for High Grade Glioma","source_id_and_acronym":"NCT06504381","lead_sponsor":"University of California, San Francisco","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • vocimagene amiretrorepvec/extended release flucytosine (DB107)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 01/08/2025","start_date":" 01/08/2025","primary_txt":" Primary completion: 01/31/2028","primary_completion_date":" 01/31/2028","study_txt":" Completion: 01/31/2042","study_completion_date":" 01/31/2042","last_update_posted":"2025-02-19"},{"id":"70012bdf-9a68-4791-98f7-f3a645c2ba06","acronym":"","url":"https://clinicaltrials.gov/study/NCT04295759","created_at":"2021-01-18T20:50:32.592Z","updated_at":"2025-02-25T14:01:55.137Z","phase":"Phase 1","brief_title":"INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas","source_id_and_acronym":"NCT04295759","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" HER-2 • CD4 • ADAM10","pipe":"","alterations":" ","tags":["HER-2 • CD4 • ADAM10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e aderbasib (INCB7839)"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 07/27/2020","start_date":" 07/27/2020","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2025-02-19"},{"id":"94c408ac-7175-4009-9855-94101a5bc215","acronym":"M23-385","url":"https://clinicaltrials.gov/study/NCT05599984","created_at":"2022-10-31T13:56:57.345Z","updated_at":"2025-02-25T14:03:07.565Z","phase":"Phase 1","brief_title":"Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05599984 - M23-385","lead_sponsor":"AbbVie","biomarkers":" EGFR • SEZ6","pipe":" | ","alterations":" EGFR mutation • IDH wild-type","tags":["EGFR • SEZ6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • budigalimab (ABBV-181) • ABBV-706"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 12/05/2022","start_date":" 12/05/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-19"},{"id":"4bdac475-2ce7-43c7-9fc6-1b82deed752b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05376800","created_at":"2022-05-17T12:54:19.363Z","updated_at":"2025-02-25T14:08:51.835Z","phase":"Phase 1","brief_title":"A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma","source_id_and_acronym":"NCT05376800","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type • IDH wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brigimadlin (BI 907828)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 11/07/2022","start_date":" 11/07/2022","primary_txt":" Primary completion: 08/29/2025","primary_completion_date":" 08/29/2025","study_txt":" Completion: 08/29/2025","study_completion_date":" 08/29/2025","last_update_posted":"2025-02-18"},{"id":"b568f31d-6b2b-46ca-879f-a90916765687","acronym":"","url":"https://clinicaltrials.gov/study/NCT05099003","created_at":"2021-10-29T14:53:11.674Z","updated_at":"2025-02-25T14:08:27.717Z","phase":"Phase 1/2","brief_title":"A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)","source_id_and_acronym":"NCT05099003","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • IDH1","pipe":" | ","alterations":" BRAF mutation • BRAF V600 • IDH1 mutation","tags":["BRAF • IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600 • IDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xpovio (selinexor)"],"overall_status":"Suspended","enrollment":" Enrollment 210","initiation":"Initiation: 05/31/2022","start_date":" 05/31/2022","primary_txt":" Primary completion: 06/30/2027","primary_completion_date":" 06/30/2027","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-02-18"},{"id":"09faeec2-6d19-4e99-bfa8-ce9ad5372038","acronym":"","url":"https://clinicaltrials.gov/study/NCT05843253","created_at":"2023-05-06T15:04:11.203Z","updated_at":"2025-02-25T14:09:40.595Z","phase":"Phase 2","brief_title":"Study of Ribociclib and Everolimus in HGG and DIPG","source_id_and_acronym":"NCT05843253","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C","pipe":" | ","alterations":" PIK3CA mutation • CDKN2A deletion","tags":["PIK3CA • PTEN • CDKN2A • RB1 • CCND1 • CDK4 • CDKN2B • PIK3R1 • CDK6 • CCND2 • CDKN2C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • CDKN2A deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Kisqali (ribociclib)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/22/2024","start_date":" 08/22/2024","primary_txt":" Primary completion: 08/28/2028","primary_completion_date":" 08/28/2028","study_txt":" Completion: 08/28/2034","study_completion_date":" 08/28/2034","last_update_posted":"2025-02-17"},{"id":"64ec7fee-f0ad-4556-bc3c-857c74e02812","acronym":"","url":"https://clinicaltrials.gov/study/NCT04145115","created_at":"2021-07-05T17:26:08.613Z","updated_at":"2025-02-25T14:07:33.392Z","phase":"Phase 2","brief_title":"A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden","source_id_and_acronym":"NCT04145115","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX","pipe":" | ","alterations":" TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type","tags":["EGFR • TP53 • CDKN2A • TERT • CDKN2B • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • EGFR mutation • EGFR amplification • CDKN2A deletion • IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)"],"overall_status":"Suspended","enrollment":" Enrollment 37","initiation":"Initiation: 12/24/2020","start_date":" 12/24/2020","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 05/31/2025","study_completion_date":" 05/31/2025","last_update_posted":"2025-02-17"},{"id":"74783677-e3f5-4018-b600-ee9dd649695b","acronym":"ST101-101","url":"https://clinicaltrials.gov/study/NCT04478279","created_at":"2021-01-18T21:30:28.794Z","updated_at":"2025-02-25T14:07:48.179Z","phase":"Phase 1/2","brief_title":"A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04478279 - ST101-101","lead_sponsor":"Sapience Therapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" HR positive • BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • Xtandi (enzalutamide) • abiraterone acetate • lucicebtide (ST101)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 07/01/2020","start_date":" 07/01/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-17"},{"id":"d494a72a-9ff2-45f5-b7e1-6d9a0c5e5875","acronym":"","url":"https://clinicaltrials.gov/study/NCT05503797","created_at":"2022-08-17T14:55:09.900Z","updated_at":"2025-02-25T14:09:04.053Z","phase":"Phase 2","brief_title":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations","source_id_and_acronym":"NCT05503797","lead_sponsor":"Fore Biotherapeutics","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e plixorafenib (FORE-8394) • Tybost (cobicistat)"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 02/21/2023","start_date":" 02/21/2023","primary_txt":" Primary completion: 06/27/2025","primary_completion_date":" 06/27/2025","study_txt":" Completion: 08/28/2026","study_completion_date":" 08/28/2026","last_update_posted":"2025-02-17"},{"id":"f6ffbda8-da78-4ee6-a86e-42e6291f385e","acronym":"","url":"https://clinicaltrials.gov/study/NCT00083512","created_at":"2021-01-18T00:14:16.293Z","updated_at":"2025-02-25T14:39:12.760Z","phase":"","brief_title":"Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme","source_id_and_acronym":"NCT00083512","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" VEGFA","pipe":"","alterations":" ","tags":["VEGFA"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 06/22/2004","start_date":" 06/22/2004","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-14"},{"id":"c6ceadea-5216-44bc-b521-a84f4461c694","acronym":"","url":"https://clinicaltrials.gov/study/NCT03389802","created_at":"2021-01-18T16:43:48.401Z","updated_at":"2025-02-25T15:10:43.667Z","phase":"Phase 1","brief_title":"Phase I Study of APX005M in Pediatric Central Nervous System Tumors","source_id_and_acronym":"NCT03389802","lead_sponsor":"Pediatric Brain Tumor Consortium","biomarkers":" TMB • TNFA • CXCL8 • CD4","pipe":"","alterations":" ","tags":["TMB • TNFA • CXCL8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sotigalimab (PYX-107)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 03/01/2018","start_date":" 03/01/2018","primary_txt":" Primary completion: 09/30/2023","primary_completion_date":" 09/30/2023","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-13"},{"id":"1ed1c0e3-9fae-4441-b5f9-6a5bb4623646","acronym":"","url":"https://clinicaltrials.gov/study/NCT04968366","created_at":"2021-07-20T14:52:28.893Z","updated_at":"2025-02-25T15:44:32.669Z","phase":"Phase 1","brief_title":"Safety \u0026 Efficacy of DC Vaccine and TMZ for the Treatment of Newly-diagnosed Glioblastoma After Surgery","source_id_and_acronym":"NCT04968366","lead_sponsor":"Beijing Tiantan Hospital","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH wild-type","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 07/30/2021","start_date":" 07/30/2021","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2025-02-11"},{"id":"2b2519dd-d5ad-49a5-8426-9dd154e0e010","acronym":"","url":"https://clinicaltrials.gov/study/NCT05241392","created_at":"2022-02-15T15:52:47.825Z","updated_at":"2025-02-25T15:27:15.182Z","phase":"Phase 1","brief_title":"Safety and Efficacy Study of Anti-B7-H3 CAR-T Cell Therapy for Recurrent Glioblastoma","source_id_and_acronym":"NCT05241392","lead_sponsor":"Beijing Tiantan Hospital","biomarkers":" CD276","pipe":"","alterations":" ","tags":["CD276"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 01/27/2022","start_date":" 01/27/2022","primary_txt":" Primary completion: 11/30/2024","primary_completion_date":" 11/30/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-11"},{"id":"451a8a7f-851d-493a-9270-889080e917a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05086497","created_at":"2021-10-21T13:53:08.372Z","updated_at":"2025-02-25T15:19:19.323Z","phase":"","brief_title":"WBSI Guided Personalized Delivery of TTFields","source_id_and_acronym":"NCT05086497","lead_sponsor":"Abramson Cancer Center at Penn Medicine","biomarkers":" MGMT","pipe":" | ","alterations":" MGMT promoter methylation • IDH wild-type","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MGMT promoter methylation • IDH wild-type"],"overall_status":"Recruiting","enrollment":" Enrollment 155","initiation":"Initiation: 01/15/2023","start_date":" 01/15/2023","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2025-02-11"},{"id":"29c36fa3-ec25-4585-bc53-d76f48cbd87a","acronym":"GIANT","url":"https://clinicaltrials.gov/study/NCT06816927","created_at":"2025-02-25T15:46:23.088Z","updated_at":"2025-02-25T15:46:23.088Z","phase":"Phase 2","brief_title":"Trial of Glioblastoma Immunotherapy Advancement With Nivolumab and Relatlimab","source_id_and_acronym":"NCT06816927 - GIANT","lead_sponsor":"Duke University","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • relatlimab (BMS-986016)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 92","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 06/01/2029","primary_completion_date":" 06/01/2029","study_txt":" Completion: 06/01/2031","study_completion_date":" 06/01/2031","last_update_posted":"2025-02-10"}]